NEW YORK, N.Y. -- Pfizer Global Supply (PGS) announced today the results of its Logistics and Plant Network Strategy studies for the manufacturing sites and distribution centers that joined the company with the acquisition of King Pharmaceuticals.
The purpose of these two studies was to integrate King’s manufacturing and supply capabilities within the broader PGS network, and to identify opportunities to improve the network’s overall competitiveness.
Pfizer will retain all eight plants and all 12 distribution centers that presently comprise legacy Alpharma Animal Health; exit the legacy King pharmaceutical manufacturing facility in Bristol, Tenn.; complete the exit of a manufacturing site in St. Petersburg, Fla. that was announced in 2007; and consolidate the Bristol logistics center into Pfizer’s existing Memphis distribution facility.
PGS expects to exit the Bristol, Tenn., plant — which is under-utilized — in 2014. Bristol, which employs approximately 130, manufactures and packages a variety of solid and semi-solid pharmaceutical products, including Levoxyl and Cytomel (thyroid therapy) and Oxecta (pain). These products will be transferred to other sites within the PGS internal /external supply network.
The decision to exit the St. Petersburg, Fla., plant, which currently employs approximately 25, was announced by King prior to its acquisition by Pfizer and confirmed as part of the Plant Network Strategy study. St. Petersburg presently manufactures Levoxyl, which is in the process of being transferred to Bristol where it will be manufactured until it is subsequently moved elsewhere in the PGS network. Pfizer expects to exit the St. Petersburg facility over the next 12 months.
Pfizer will immediately begin the process of looking for strategic options for the Bristol plant with the goal of
maintaining as many jobs as possible. This process has already begun for the St. Petersburg site. However, success in finding options for these facilities is uncertain given the aggressive implementation timelines and the current weak demand for pharmaceutical manufacturing facilities.
In addition to these decisions on manufacturing facilities, PGS will exit the Bristol, Tenn., Logistics Center in 2012 and pursue strategic options for the future use of that site. A number of the products handled there will be consolidated into Pfizer’s existing Memphis Logistics Center. Other products and materials will be managed externally. The Bristol operation, which is part of PGS Global Logistics and Supply, employs approximately 16. The consolidation will result in creation of several new jobs at the Memphis Center.